{
    "Trade/Device Name(s)": [
        "Innovacon Spectrum II Test Card",
        "Innovacon Spectrum II Test Card with Integrated Cups",
        "Innovacon 014 Cup",
        "E-Z Action Multi-Drug Test Cup",
        "Innovacon 022 Cup",
        "E-Z Start Multi-Drug Test Cup"
    ],
    "Submitter Information": "INNOVACON Laboratories, Inc.",
    "510(k) Number": "K061718",
    "Predicate Device Reference 510(k) Number(s)": [
        "K031759",
        "K032903",
        "K033299",
        "K040445",
        "K041822",
        "K043507",
        "K060466"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LDJ",
        "DIO",
        "DJC",
        "DKZ",
        "DJG",
        "LCM",
        "JXM",
        "DJR",
        "DIS",
        "LFG",
        "LAF",
        "JXN"
    ],
    "Summary Letter Date": "November 13, 2006",
    "Summary Letter Received Date": "October 23, 2006",
    "Submission Date": "October 20, 2006",
    "Regulation Number(s)": [
        "21 CFR 862.3870",
        "21 CFR 862.3250",
        "21 CFR 862.3610",
        "21 CFR 862.3100",
        "21 CFR 862.3650",
        "21 CFR 862.3170",
        "21 CFR 862.3620",
        "21 CFR 862.3150",
        "21 CFR 862.3910",
        "21 CFR 862.3700"
    ],
    "Regulation Name(s)": [
        "Amphetamine test system",
        "Cocaine test system",
        "Marijuana test system",
        "Benzodiazepines test system",
        "Tricyclic Antidepressants test system",
        "Barbiturates test system",
        "Morphine test system",
        "Phencyclidine test system",
        "Oxycodone test system",
        "Propoxyphene test system",
        "Methadone test system",
        "Opiate test system",
        "Methylenedioxymethamphetamine test system",
        "Buprenorphine test system",
        "Methamphetamine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Amphetamine",
        "Cocaine",
        "Marijuana",
        "Benzodiazepines",
        "Tricyclic Antidepressants",
        "Barbiturates",
        "Morphine",
        "Phencyclidine",
        "Oxycodone",
        "Propoxyphene",
        "Methadone",
        "Opiate",
        "Methylenedioxymethamphetamine",
        "Buprenorphine",
        "Methamphetamine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "Innovacon 014 Cup",
        "E-Z Action Multi-Drug Test Cup",
        "Innovacon 022 Cup",
        "E-Z Start Multi-Drug Test Cup"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Lateral flow immunochromatographic assay",
        "Competitive binding immunoassay"
    ],
    "Methodologies": [
        "Chromatographic immunoassay",
        "Lateral flow assay"
    ],
    "Submission Type(s)": [
        "Test Card",
        "Cup",
        "Multi-Drug Test Cup"
    ],
    "Document Summary": "FDA 510(k) summary for Innovacon Spectrum II Test Card and Test Card with Integrated Cups for simultaneous qualitative detection of drugs of abuse in urine by lateral flow immunochromatographic assay.",
    "Indications for Use Summary": "Qualitative, simultaneous detection of marijuana, cocaine, methylenedioxymethamphetamine, amphetamine, morphine, opiates, methadone, methamphetamine, phencyclidine, benzodiazepine, oxycodone, propoxyphene, tricyclic antidepressants, buprenorphine, and barbiturate in urine for healthcare professionals at point-of-care sites; results are preliminary and require confirmatory testing.",
    "fda_folder": "Toxicology"
}